AUSPEX PHARMACEUTICALS, INC. (ASPX) financial statements (2021 and earlier)

Company profile

Business Address 3333 N. TORREY PINES COURT
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments145159112120
Cash and cash equivalents30901527
Short-term investments115709793
Receivables10  
Prepaid expense0111
Deferred costs0 0 
Other undisclosed current assets5500
Total current assets:151166113121
Noncurrent Assets
Property, plant and equipment0000
Regulated entity, other noncurrent assets   4
Deferred costs   1
Other noncurrent assets0000
Other undisclosed noncurrent assets0 0(4)
Total noncurrent assets:0010
TOTAL ASSETS:151166114121
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14976
Accounts payable7321
Accrued liabilities5544
Employee-related liabilities3211
Debt 1  
Other undisclosed current liabilities(3)(2)(1)(1)
Total current liabilities:11965
Noncurrent Liabilities
Long-term debt and lease obligation15131515
Long-term debt, excluding current maturities15131515
Liabilities, other than long-term debt0000
Other liabilities0000
Other undisclosed noncurrent liabilities   (1)
Total noncurrent liabilities:15141515
Total liabilities:26232119
Stockholders' equity
Stockholders' equity attributable to parent, including:12113992102
Common stock0000
Additional paid in capital246245178177
Accumulated other comprehensive income (loss) (0)0(0)
Accumulated deficit(125)(105)(86) 
Other undisclosed stockholders' equity attributable to parent   (76)
Stockholders' equity attributable to noncontrolling interest44  
Total stockholders' equity:12514492102
TOTAL LIABILITIES AND EQUITY:151166114121

Income statement (P&L) ($ in millions)

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
Operating expenses(20)(14)(10)(6)
Operating loss:(20)(14)(10)(6)
Nonoperating income (expense)0(5)(0)(4)
Investment income, nonoperating00 (0)
Other nonoperating income00 4
Interest and debt expense(1)(1)(0) 
Loss before gain (loss) on sale of properties:(21)(20)(10)(10)
Other undisclosed net income11  
Net loss:(20)(19)(10)(10)
Net loss attributable to noncontrolling interest(0)(0)  
Other undisclosed net income attributable to parent  0 
Net loss available to common stockholders, diluted:(20)(19)(10)(10)

Comprehensive Income ($ in millions)

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
Net loss:(20)(19)(10)(10)
Other comprehensive income (loss) (0)0(0)
Other undisclosed comprehensive income0   
Comprehensive loss:(20)(19)(10)(10)
Comprehensive loss, net of tax, attributable to noncontrolling interest(0)(0)  
Other undisclosed comprehensive income, net of tax, attributable to parent  0 
Comprehensive loss, net of tax, attributable to parent:(20)(19)(10)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: